diffuse large B-cell lymphoma (DLBCL)

mountain climb steep challenge point path red flag
Biotech

Regeneron seeks clarity on confirmatory trials after FDA hurdle

Regeneron's Andres Sirulnik says blood cancer medicine odronextamab enrollment is going fine, days after FDA rejection.
Annalee Armstrong Mar 29, 2024 5:00am
Elm tree

ASH: Regeneron’s near-approval bispecific shines again

Dec 11, 2023 5:25am
Finger touching search engine bar

Cancer biotech IMV hunts for a deal as its cash clock ticks down

Mar 16, 2023 8:28am
target goal darts

ASH: Regeneron lymphoma med scores but safety muffles excitement

Dec 12, 2022 5:30pm
Regeneron

ASH: Regeneron readies bispecific data—but deaths cast shadow

Dec 12, 2022 7:30am
layoffs layoff exit cut employees staff downsize workforce reduction

IMV drops 3rd of staff in refocus on lead oncology asset

Sep 15, 2022 9:45am